Abstract
Just 15 months after RET fusions were first identified in 1%–2% of NSCLC cases, early data from a Phase II trial of Exelixis' Cometriq suggest that blocking the target could be effective in this patient population. At least four additional investigator-initiated trials are testing marketed RET inhibitors in patients with fusion-positive lung cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
